Status:
TERMINATED
Vascular Dysfunction in Hypertensive Postmenopausal Women
Lead Sponsor:
University of Delaware
Collaborating Sponsors:
National Institutes of Health (NIH)
Conditions:
Cardiovascular Diseases
Hypertension
Eligibility:
FEMALE
50-70 years
Phase:
PHASE4
Brief Summary
The purpose of this study is to investigate the role of ET-1 in mediating vasoconstrictor tone in hypertensive postmenopausal women (PMW) alone and in combination with a commonly prescribed Angiotensi...
Detailed Description
Cardiovascular disease (CVD) is the leading cause of death in women, and mortality from CVD is higher in PMW compared to age-matched men. PMW are at a greater risk for developing HTN, a major risk fac...
Eligibility Criteria
Inclusion
- Women.
- \> 1year post menopausal.
- Age range 50-70 years
- Resting ECG in normal limits
- Standard blood chemistry within normal limits
- Systolic blood pressure: \<130mm Hg for normotensives; \>130mm Hg for hypertensives.
- Diastolic blood pressure: \< 80mm Hg for normotensives; \> 80mm Hg for hypertensives.
Exclusion
- History of cardiovascular disease
- Blood clots or stroke
- Cancer
- Diabetes
- Kidney or Liver disease
- Obesity (BMI\>35kg/m2)
- Pregnant/Breast feeding
- Current use of hormone therapy
- Current use of tobacco products
- High cholesterol
- Current use of anti-hypertensive meds
Key Trial Info
Start Date :
September 1 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 31 2019
Estimated Enrollment :
8 Patients enrolled
Trial Details
Trial ID
NCT03371823
Start Date
September 1 2017
End Date
December 31 2019
Last Update
January 19 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Delaware
Newark, Delaware, United States, 19716